Trillium Therapeutics Inc. (TRIL) Income Statement Analysis

See more : Jindal Photo Limited (JINDALPHOT.BO) Income Statement Analysis – Financial Results

Complete financial analysis of Trillium Therapeutics Inc. (TRIL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Trillium Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Trillium Therapeutics Inc. (TRIL)

Industry: Biotechnology

Sector: Healthcare

Website: http://trilliumtherapeutics.com

About Trillium Therapeutics Inc.

Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622 that is in Phase I clinical trial of immunoglobulin G4 SIRPaFc protein; and TTI-10001, a small molecule stimulator of interferon genes agonist that senses cytosolic DNA for promoting tumor immunity, which is in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 is headquartered in Mississauga, Canada.

Metric	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004
Revenue	148.00K	124.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	147.85K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	148.00	124.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit Ratio	0.10%	100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Research & Development	25.35M	25.30M	31.88M	29.53M	22.16M	13.01M	9.13M	3.13M	626.79K	818.29K	1.76M	2.26M	2.22M	1.87M	1.85M	888.00K	171.39K
General & Administrative	36.26M	4.31M	2.63M	3.07M	2.93M	2.29M	2.22M	903.67K	468.71K	1.41M	2.44M	1.92M	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	36.26M	4.31M	2.63M	3.07M	2.93M	2.29M	2.22M	903.67K	468.71K	1.41M	2.44M	1.92M	0.00	0.00	0.00	0.00	0.00
Other Expenses	0.00	3.01M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	902.08K	269.33K	287.57K	2.41M	3.52M	-6.01M	1.78M	559.18K
Operating Expenses	61.60M	32.61M	34.51M	32.60M	25.09M	15.30M	11.35M	4.04M	1.10M	3.13M	4.47M	4.47M	4.63M	5.38M	-4.16M	2.67M	730.58K
Cost & Expenses	61.60M	35.56M	34.51M	32.60M	25.09M	15.30M	11.35M	4.04M	1.10M	3.13M	4.47M	4.47M	4.63M	5.38M	-4.16M	2.67M	730.58K
Interest Income	2.01M	614.00K	795.87K	574.16K	310.63K	352.01K	326.22K	41.43K	25.87K	35.66K	8.06K	18.85K	191.64K	0.00	85.68K	136.08K	0.00
Interest Expense	0.00	177.00K	31.57K	54.08K	48.63K	52.89K	60.10K	37.69K	0.00	14.03K	0.00	0.00	133.84K	0.00	284.56K	307.87K	0.00
Depreciation & Amortization	591.00K	2.11M	2.31M	3.74M	3.19M	329.86K	566.81K	609.32K	6.42K	250.35K	258.05K	257.54K	227.09K	285.51K	246.01K	235.71K	53.07K
EBITDA	-58.65M	-39.31M	-28.85M	-32.05M	-23.11M	-10.23M	-10.47M	-3.38M	-1.06M	-2.84M	-4.20M	-4.19M	-4.21M	-5.22M	-3.55M	-2.27M	-737.08K
EBITDA Ratio	-39,630.41%	-31,702.42%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Income	-61.46M	-35.44M	-34.51M	-32.60M	-25.09M	-15.30M	-11.35M	-4.04M	-1.10M	-3.13M	-4.47M	-4.47M	-4.63M	-5.38M	4.16M	-2.67M	-730.58K
Operating Income Ratio	-41,523.65%	-28,579.03%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Total Other Income/Expenses	2.21M	-6.16M	3.33M	-3.25M	-1.26M	4.69M	251.06K	9.01K	28.48K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income Before Tax	-59.24M	-41.59M	-31.19M	-35.85M	-26.35M	-10.61M	-11.10M	-4.03M	-1.07M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income Before Tax Ratio	-40,029.73%	-33,543.55%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Income Tax Expense	102.00K	28.00K	5.87K	3.18K	-2.74M	6.85K	311.16K	46.71K	28.48K	14.03K	0.00	0.00	133.84K	0.00	284.56K	307.87K	0.00
Net Income	-59.35M	-41.62M	-31.19M	-35.86M	-23.61M	-10.62M	-11.10M	-4.03M	-1.07M	-3.11M	-4.46M	-4.45M	-4.57M	-5.51M	-4.08M	-2.82M	-790.15K
Net Income Ratio	-40,098.65%	-33,566.13%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	-0.71	-1.65	-2.24	-3.67	-3.02	-1.60	-2.64	-2.97	-17.15	-5.11	-8.53	-9.76	-12.41	-23.10	-23.16	-15.50	-0.01
EPS Diluted	-0.71	-1.65	-2.24	-3.67	-3.02	-1.60	-2.64	-2.97	-17.15	-5.11	-8.53	-9.76	-12.41	-23.10	-20.36	-14.13	-0.01
Weighted Avg Shares Out	83.75M	25.26M	13.91M	9.77M	7.82M	6.64M	4.20M	1.36M	62.21K	608.26K	522.68K	455.62K	368.01K	238.38K	176.29K	181.67K	105.00M
Weighted Avg Shares Out (Dil)	83.75M	25.26M	13.91M	9.77M	7.82M	6.64M	4.20M	1.36M	62.21K	608.26K	522.68K	455.62K	368.01K	238.38K	200.54K	199.29K	105.00M

Trillium Therapeutics: A Potentially Undervalued CD47 Player

January 18, 2021seekingalpha.com

Trillium Therapeutics has two lead candidates that encourage immune cells known as “macrophages” to gobble up cancer cells by blocking a protein known as CD47. However, the CD47 inhibitor space is incredibly crowded. There are 10+ groups developing a drug...

3 Top Biotech Picks for January

January 13, 2021fool.com

Buy these three biotech stocks before they take off.

1 Big Reason Trillium Therapeutics Stock's Hot Streak Will Continue in 2021

January 12, 2021fool.com

When it comes to countering a key trick that cancer plays on the human immune system, this biotech has no equal.

The Worst Mistake Trillium Investors Can Make Right Now

January 4, 2021fool.com

The company's long-term plan is to challenge conventional cancer therapy.

My Favorite Biotech Stock for 2021

January 4, 2021fool.com

This clinical-stage biotech stock could be a top buyout candidate in 2021.

5 Biotech Stocks That Generated 1,000%+ Returns In 2020

December 26, 2020feeds.benzinga.com

The biopharma sector weathered the COVID-19 pandemic fairly well, with the Shares Nasdaq Biotechnology Etf (NASDAQ: IBB) outperforming the S&P 500 Index. This defensive sector also benefited from opportunity in the form of SARS-CoV-2, the virus that causes COVID-19.